Thrivent Financial for Lutherans Trims Holdings in IQVIA Holdings Inc. $IQV

Thrivent Financial for Lutherans lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.0% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 38,358 shares of the medical research company’s stock after selling 3,326 shares during the quarter. Thrivent Financial for Lutherans’ holdings in IQVIA were worth $6,045,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Canada Pension Plan Investment Board lifted its stake in IQVIA by 7.3% in the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after acquiring an additional 312,807 shares during the period. Alliancebernstein L.P. raised its holdings in IQVIA by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of IQVIA in the 2nd quarter worth about $515,772,000. JPMorgan Chase & Co. increased its position in shares of IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after buying an additional 581,157 shares during the period. Finally, Nordea Investment Management AB raised its stake in IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Stifel Nicolaus boosted their target price on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Morgan Stanley upped their target price on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $243.19.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Down 0.8%

IQVIA stock opened at $220.75 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. The company has a market capitalization of $37.59 billion, a price-to-earnings ratio of 30.28, a price-to-earnings-growth ratio of 2.50 and a beta of 1.37. The business’s fifty day simple moving average is $219.06 and its two-hundred day simple moving average is $192.18. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.